An adrenaline rush is a colloquial expression about the feeling of exhilaration and heightened energy that is brought on by ...
Investor's Business Daily on MSN6h
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.Shares of ARS Pharmaceuticals bounded off their 50-day line Thursday after the biotech company reported an unexpected ...
ARS Pharmaceuticals, Inc.'s stock soared 25% on strong earnings. Learn about neffy's market potential, risks, and future ...
The US Food and Drug Administration (FDA) has approved Neffy, a nasal spray for treating severe allergic reactions in ...
Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions in children aged 4 ...
Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments ...
US FDA approves ARS Pharma’s neffy 1 mg to treat type I allergic reactions for paediatric patients weighing 15 to less than 30 kilograms: San Diego Friday, March 7, 2025, 09:00 ...
Whether finding new treatments for schizophrenia or first-time ways to tackle bladder cancer, these companies are finding ...
9hon MSN
Q4 2024 Management View Richard Lowenthal, Co-Founder and CEO, highlighted the successful launch of neffy 2mg in the U.S. and the FDA approval for neffy 1mg for pediatric use, targeting children ...
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results